Medical/Pharmaceuticals

New International Consensus on CGM Clinical Trial Metrics Aims to Spur Diabetes Treatment Advances

SAN FRANCISCO, Dec. 7, 2022 /PRNewswire/ -- The diaTribe Foundation, Advanced Technologies & Treatments for Diabetes (ATTD), and the Time in Range Coalition announced today a new international consensus regarding continuous glucose monitoring (CGM) metrics for clinical trials to help accelerate t...

2022-12-07 01:26 2701

Healthcare Summit Convened to Address Maternal-Fetal Outcomes in Sub-Saharan Africa

ROCKVILLE, Md., Dec. 6, 2022 /PRNewswire/ -- Inteleos, a non-profit global healthcare certification organization and Kenya Healthcare Federation, a membership-based organization that serves as the umbrella body forKenya's Private Health Sector, hosted a maternal and fetal ultrasound summit onNov....

2022-12-06 23:00 2673

Turn Biotechnologies Changes Paradigm in Skin Rejuvenation

* Data unveiled at four industry conferences suggest a single ERA treatment may be more effective than combination therapies used today * Biomarker analysis demonstrates ERA's regenerative impact on fibroblast proliferation, collagen VII production * eTurna™ lipid-based delivery platform p...

2022-12-06 22:00 4976

CORVIA MEDICAL ANNOUNCES RANDOMIZATION OF FIRST PATIENT IN THE RESPONDER-HF CONFIRMATORY TRIAL

Corvia® Atrial Shunt has the potential to change the way heart failure is treated TEWKSBURY, Mass., Dec. 6, 2022 /PRNewswire/ -- Corvia Medical, Inc., a company dedicated to transforming the treatment of heart failure (HF), announced the first patient has been randomized in RESPONDER-HF, a globa...

2022-12-06 20:04 2156

Clarivate Expands Real World Data and Analytics Solutions with Addition of U.S. Specialty Pharmacy Data

LONDON, Dec. 6, 2022 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a global leader in providing trusted information and insights to accelerate the pace of innovation, today announced the inclusion of linked specialty pharmacy claims data within real world datasolutions. The new U.S. dataset will ex...

2022-12-06 18:20 2998

GenScript ProBio Congratulates Selecxine's IND Clearance from MFDS

SEOUL, South Korea, Dec. 6, 2022 /PRNewswire/ -- Recently, Selecxine, a partner of GenScript ProBio, announced MFDS clearance of its phase I/II clinical trial application for innovative antibody drug program (SLC-3010) . GenScript ProBio extended congratulations on this. SinceDecember 2019, GenSc...

2022-12-06 17:14 3999

University of Tokyo and Sekisui House Launch Joint Research on Biodiversity and Health

TOKYO, Dec. 6, 2022  /PRNewswire/ -- - World's First Research into Relationship between Rich-in-Biodiversity Garden Greenery and Health/Well-being - The University of Tokyo's Graduate School of Agricultural and Life Sciences (GSALS) and Sekisui House, Ltd. launched a joint research project on b...

2022-12-06 14:00 1909

BSR KOREA Introduces "Healcerion Co., Ltd." as "2022 Global Procurement Marketer"

SEOUL, South Korea, Dec. 6, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...

2022-12-06 11:00 3551

BSR KOREA Introduces "CORE VALUE" as "2022 Global Procurement Marketer"

SEOUL, South Korea, Dec. 6, 2022 /PRNewswire/ -- As the practitioner of "2022 Global Procurement Marketer (GPM) Project" promoted by the Ministry of SMEs and Startups (MSS) and Korea SMEs and Startups Agency (KOSME), BSR KOREA offered consultation for 40 domestic SMEs that want to enter the inter...

2022-12-06 11:00 2963

Neeuro and Institute of Mental Health Launch Home-Based Attention Training Programme

SINGAPORE, Dec. 6, 2022 /PRNewswire/ -- Neeuro, a Singapore tech start-up and Agency for Science, Technology and Research (A*STAR) spinoff, and the Institute of Mental Health (IMH) launched Cogo as a complementary home-based attention training programme this month. This solution aims to improve i...

2022-12-06 09:00 7600

Medical Metaverse Company, apoQlar, Receives FDA 510(k) Clearance for its Mixed Reality Surgical Planning Platform, VSI HoloMedicine®

HAMBURG, Germany, Dec. 5, 2022 /PRNewswire/ -- apoQlar, a German medical technology company, today announced it has received FDA 510(k) Class II clearance for VSI HoloMedicine®, a pioneering mixed reality software device enabling surgeons to plan complex procedures using the power of immersive 3D...

2022-12-05 21:00 3069

Program CD47, provided the CMC service by GenScript ProBio to InnobationBio, will further be advanced by the joint venture between Liminatus Pharma LLC and Iris Acquisition Corp

NEW YORK and LONDON, Dec. 5, 2022 /PRNewswire/ -- Recently, Liminatus Pharma LLC ("Liminatus"), a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies and Iris Acquisition Corp ("Iris") (Nasdaq: IRAA), a publicly traded special purpose acquisition company ...

2022-12-05 20:00 2810

Lynk Pharmaceuticals Announces First Patient Dosed in Phase Ⅱ Clinical Study of LNK01003 in Patients with Ulcerative Colitis

HANGZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as 'Lynk Pharmaceuticals'), an innovative clinical stage company, announced that it has dosed the first patient in a Phase II clinical trial of its innovative drug LNK01003 in Ulcerative Colitis ...

2022-12-05 08:00 4128

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

ROCKVILLE, Md. and SUZHOU, China, Dec. 5, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and...

2022-12-05 08:00 4742

Telix Announces Executive Leadership Appointments

MELBOURNE, Australia, Dec. 5, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces several key executive leadership appointments and promotions, reflecting the increased commercial focus of the Company and ongoing succession planning.  Richard Valei...

2022-12-05 06:39 3038

FOUNDATION FOR ANGELMAN SYNDROME THERAPEUTICS (FAST) ANNOUNCES $5 MILLION GIFT TO ADVANCE CLINICAL TRIALS IN RARE NEURODEVELOPMENTAL DISORDERS

The Center at Rush University Will Be Directed By Dr. Elizabeth Berry-Kravis MIAMI, Dec. 3, 2022 /PRNewswire/ -- The Foundation for Angelman Syndrome Therapeutics (FAST) announced today a$5 million gift to establish the new clinical trial and translational research effort for rare neurodevelopmen...

2022-12-03 01:07 4955

Epiprotect reduces the cost for treatment of hard to heal leg ulcers with 83%

LINKÖPING, Sweden, Dec. 3, 2022 /PRNewswire/ -- A compilation of data from patients treated at S2Clinic during the period 2019-2022 showed that the cost of treatment of these patients was reduced by approximately 83% compared to conventional treatment. The treatment with Epiprotect also resulted ...

2022-12-03 00:41 3617

Cure Brain Cancer Foundation Rings Nasdaq Opening Bell, Announces U.S. Expansion

CEO Lance Kawaguchi Drives Effort & Brings Compelling Personal Story to Global Battle Against Cancer NEW YORK, Dec. 3, 2022 /PRNewswire/ -- Cure Brain Cancer Foundation CEO Lance Kawaguchi rang the bell to open trading on the Nasdaq stock exchange on Friday morning,December 2. The Foundation ann...

2022-12-02 23:00 3725

Sirolimus Coated Balloon in BTK Treatment makes a bold presence at VEITH 2022 - Lights up NY Times Square, NASDAQ

TAMPA, Fla., Dec. 2, 2022 /PRNewswire/ -- VEITH 2022 witnessed a surge of supporting clinical data for Sirolimus Coated Balloon in the treatment of Below-the-Knee (BTK) disease.Concept Medical Inc . hosted a lunch symposium titled 'Sirolimus Coated Balloon in PAD...

2022-12-02 21:10 5325

Focus-X Therapeutics, a Viva Biotech Portfolio Company, Successfully Reached an Acquisition Agreement with Full-Life Technologies

JERSEY CITY, N.J. and SHANGHAI, Dec. 2, 2022 /PRNewswire/ -- Focus-X Therapeutics (referred to here as "Focus-X"), a nuclide drug company that was invested in and incubated by Viva Biotech, successfully reached an acquisition agreement with Full-Life Technologies Co., Ltd. (referred to here as "...

2022-12-02 18:23 4846
1 ... 276277278279280281282 ... 381

Week's Top Stories